Vanderbilt Institute for Clinical and Translational Research (VICTR) -Identifying correlates of functional immunity in SARS-CoV-2 convalescent plasma

范德比尔特临床和转化研究所 (VICTR) - 识别 SARS-CoV-2 恢复期血浆中功能免疫的相关性

• 批准号: 10254565
• 负责人: Gordon R Bernard
• 金额: $ 56.3万
• 依托单位: VANDERBILT UNIVERSITY MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-18 至 2022-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10254565
• 关键词: 2019-nCoV; Agreement; Antibodies; Binding; Biological Assay; COVID-19; COVID-19 pandemic; Cessation of life; Clinical Research; Clinical Trials Design; Collaborations; Communities; Country; Data; Data Collection; Ensure; Health Sciences; Immunity; Individual; Infection; Informatics; Institutes; Institution; Knowledge; Legal; Measurable; Measures; Medical; Methodology; Methods; Mission; Multi-Institutional Clinical Trial; Outcome; Participant; Plasma; Randomized Clinical Trials; Readiness; Research; Research Infrastructure; Resources; Safety; Science; Transfusion; Translational Research; Translations; United States; Viral; Virus; clinical efficacy; drug development; improved; novel; patient subsets; pragmatic trial; programs; recruit; service programs; skills; translational study

The Vanderbilt Institute for Clinical and Translational Research (VICTR) is a highly functional and integrated clinical and translational (C&T) research infrastructure that has raised the quality and scientific rigor of the research conducted at Vanderbilt and longstanding partner Meharry, the nation's oldest historically black academic health science institution. VICTR will contribute to the mission of the CTSA program while leveraging unique resources and expertise within VICTR's Hub with these aims: 1) Leverage VICTR's strong collaborative energy to enhance team science methodologies that propel transdisciplinary research approaches, and integrate proven community engagement principles to stakeholders for all stages of research; 2) Develop, implement and disseminate informatics and data organization methods to promulgate research efficiency, quality, and preparedness and integrate data collection in the conduct of pragmatic trials; 3) Ensure the translational science workforce is diverse and has the skills, knowledge, and resources necessary to advance translation of discoveries; 4) Measurably improve the efficiency, quality, and representativeness of C&T studies by enhancing and systematically integrating services and programs that support highest quality research initiation and conduct; 5) Measurably improve the efficiency and quality of multi-site clinical trials, in collaboration with the TICs and RICs, by leveraging centralized regulatory and legal agreements, providing rapid feasibility and recruitment methods and practices, and creating and disseminating novel clinical trial designs and methodologies; and 6) Utilize unique strengths leveraging novel resources BioVU and PheWAS to guide drug development and repurposing.

范德比尔特临床与转化研究所 (VICTR) 是一个功能强大的机构 以及综合的临床和转化 (C&T) 研究基础设施，提高了质量 以及范德比尔特大学和长期合作伙伴 Meharry 进行的研究的科学严谨性， 美国历史最悠久的黑人学术健康科学机构。 VICTR 将致力于 CTSA 计划的使命，同时利用内部独特的资源和专业知识 VICTR 中心的目标如下： 1) 利用 VICTR 强大的协作能力来增强 团队科学方法论推动跨学科研究方法，并整合 在所有研究阶段向利益相关者提供经过验证的社区参与原则； 2）开发， 实施和传播信息学和数据组织方法以推广研究 效率、质量和准备情况，并将数据收集整合到务实的实施中 试验； 3) 确保转化科学队伍的多元化并拥有技能、知识、 以及推进发现转化所需的资源； 4) 显着改善 通过加强和系统地提高C&T研究的效率、质量和代表性 整合支持最高质量研究启动和实施的服务和计划； 5) 与以下机构合作，显着提高多中心临床试验的效率和质量 TIC 和 RIC 通过利用集中监管和法律协议，提供快速 可行性和招募方法和实践，并创造和传播新的临床 试验设计和方法； 6）利用独特的优势和新颖的资源 BioVU 和 PheWAS 指导药物开发和再利用。